Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer
单位:[1]Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China[2] Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China[3] The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China[4] Sun Yat-sen University Cancer Center, Guangzhou, China[5] The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China[6] Beijing Friendship Hospital affiliated to Capital Medical University, Beijing, China首都医科大学附属北京友谊医院
出处:
ISSN:
基金:
National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality
第一作者单位:[1]Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China[2] Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China[3] The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China[4] Sun Yat-sen University Cancer Center, Guangzhou, China[5] The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China[6] Beijing Friendship Hospital affiliated to Capital Medical University, Beijing, China
推荐引用方式(GB/T 7714):
Dong Baijun,Fan Liancheng,Yang Bin,et al.Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer[J].JOURNAL of CLINICAL ONCOLOGY.2020,38(6):
APA:
Dong, Baijun,Fan, Liancheng,Yang, Bin,Chen, Wei,Li, Yonghong...&Xue, Wei.(2020).Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer.JOURNAL of CLINICAL ONCOLOGY,38,(6)
MLA:
Dong, Baijun,et al."Circulating tumor DNA-targeted sequencing to reveal germline and somatic alterations that can guide decision-making in metastatic castration-resistant prostate cancer".JOURNAL of CLINICAL ONCOLOGY 38..6(2020)